About GRANDPHARMA Company

The Group is a technologically innovative international pharmaceutical enterprise. Its core business spans the three fields of pharmaceutical technology, nuclear drug anti-tumor diagnosis and treatment, cardiovascular precision interventional diagnosis and treatment technology, and biotechnology. The Group is based on the pharmaceutical and biological industries, with patients' needs as the core, scientific and technological innovation as the driving force. In response to unmet clinical needs, the Group will increase investment in global innovative products and advanced technology, enrich and improve product pipelines, consolidate and strengthen the industrial chain layout, give full play to the Group's industrial advantages and R&D capabilities, and provide more advanced and diverse treatment plans for patients around the world. Through unremitting efforts in recent years, the Group's development foundation has become more stable, the scale of operation has been consolidated, its business structure has been gradually optimized, its business methods have continued to improve, the pace of transformation and upgrading has accelerated, and its innovative layout has blossomed more. The Group's profitability continues to increase, helping R&D and innovation; its good mergers and acquisitions and integration capabilities continue to consolidate the scale of development; integrating raw materials and formulations to improve the structure of the industrial chain; and diversification of business and entities, effectively strengthening its comprehensive advantages. “Steady Growth, Strong Innovation, and Strategy Planning”, the Group will continue to focus on meeting patients' needs, follow the direction of market development, adhere to scientific and technological innovation as the driving force, adhere to the development concept of “comprehensive advantage, innovation leadership and global expansion”, and adopt the strategy of “independent R&D and global expansion of two-wheel drive, global operation layout and dual cycle business development” to form a new pattern of dual cycle joint development and mutual promotion at home and abroad. It is committed to becoming a technologically innovative international pharmaceutical enterprise respected by doctors and patients and restored to society.